Syringic acidCAS# 530-57-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 530-57-4 | SDF | Download SDF |
PubChem ID | 10742 | Appearance | Light brown powder |
Formula | C9H10O5 | M.Wt | 198.2 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Synonyms | Cedar acid; Gallic acid 3,5-dimethyl ether; 4-Hydroxy 3,5-dimethoxybenzoic acid | ||
Solubility | DMSO : 62.5 mg/mL (315.39 mM; Need ultrasonic) | ||
Chemical Name | 4-hydroxy-3,5-dimethoxybenzoic acid | ||
SMILES | COC1=CC(=CC(=C1O)OC)C(=O)O | ||
Standard InChIKey | JMSVCTWVEWCHDZ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C9H10O5/c1-13-6-3-5(9(11)12)4-7(14-2)8(6)10/h3-4,10H,1-2H3,(H,11,12) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Syringic acid is a potential antioxidant used in traditional Chinese medicine and is an emerging nutraceutical. It has potential anti-angiogenic, anti-glycating, anti-hyperglycaemic,antimicrobial, fungitoxicity, neuroprotective, antimitogenic, chemo-sensitizing, anti-obesity, anti-inflammatory, anti-steatotic, and memory-enhancing properties. Syringic acid can ameliorate L-arginine methyl ester-induced hypertension by reducing oxidative stress, and can reduce the pancreatic damage induced by alloxan and stimulated β-cell regeneration in diabetic rats. Syringic acid can suppress hepatic fibrosis in chronic liver injury, it inhibits the activation of cultured hepatic stellate cells. |
Targets | Caspase | IFN-γ | IL Receptor | TNF-α | NF-kB | NO | Antifection |
In vitro | Syringic acid from Tamarix aucheriana possesses antimitogenic and chemo-sensitizing activities in human colorectal cancer cells.[Pubmed: 23745612]Pharm Biol. 2013 Sep;51(9):1110-24.For its variety of biological activities, Tamarix aucheriana (Decne.) Baum. (Tamaricaceae) has an extensive history as a traditional Arab medicine.
Antimitogenic and chemo-sensitizing activities of Syringic acid (SA) were studied against human colorectal cancer.
In Vitro Antimicrobial Activity and Fungitoxicity of Syringic Acid, Caffeic Acid and 4-hydroxybenzoic Acid against Ganoderma Boninense.[Reference: WebLink]J. Agr. Sci., 2009, 1(2):15-20.This paper discusses the in vitro antimicrobial activity and fungitoxicity of Syringic acid, caffeic acid and4-hydroxybenzoic acid which is found in oil palm root.
|
In vivo | The protective effect of syringic acid on ischemia injury in rat brain.[Pubmed: 25790559]Turk J Med Sci. 2015;45(1):233-40.Brain ischemia and treatment are important topics in neurological science. Free oxygen radicals and inflammation formed after ischemia are accepted as the most significant causes of damage. Currently there are studies on many chemopreventive agents to prevent cerebral ischemia damage. Our aim is to research the preventive effect of the active ingredient in Syringic acid, previously unstudied, on oxidative damage in cerebral ischemia.
The Neuroprotective Effect of Syringic Acid on Spinal Cord Ischemia/Reperfusion Injury in Rats.[Pubmed: 25903968]Inflammation. 2015 Apr 23.Acute arterial occlusions via different vascular pathologies are the main causes of spinal cord ischemia. We investigated neuroprotective effects of Syringic acid on spinal cord ischemia injury in rats.
Antihyperglycemic effect of syringic acid on attenuating the key enzymes of carbohydrate metabolism in experimental diabetic rats.[Reference: WebLink]Biomedicine & Preventive Nutrition, 2014, 4(4):595-602.Diabetes mellitus is one of the most common endocrine entities, which coexist with defect in carbohydrate metabolism. The Indian traditional system of medicine prescribed plant phytochemical therapies for diseases including diabetes mellitus.
|
Animal Research | Hepatoprotective effect of syringic acid and vanillic acid on CCl4-induced liver injury.[Pubmed: 20522963]Syringic acid ameliorates (L)-NAME-induced hypertension by reducing oxidative stress.[Pubmed: 23079793]Antioxidant Activity of Syringic Acid Prevents Oxidative Stress in l-arginine-Induced Acute Pancreatitis: An Experimental Study on Rats.[Pubmed: 26011211]Anti-steatotic and anti-inflammatory roles of syringic acid in high-fat diet-induced obese mice.[Pubmed: 26838182 ]Food Funct. 2016 Feb;7(2):689-97.This study examined the effects of Syringic acid (SA) on obese diet-induced hepatic dysfunction.
Int Surg. 2015 May;100(5):891-6.The aim of this study was to investigate the possible protective role of antioxidant treatment with Syringic acid (SA) on l-arginine-induced acute pancreatitis (AP) using biochemical and histopathologic approaches.
Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1175-84.The objective of the present study was to investigate the effects of Syringic acid (SA), a phenolic acid, on N(ω)-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats.
Biol Pharm Bull. 2010;33(6):983-7.The mycelia of the edible mushroom Lentinula edodes can be cultured in solid medium containing lignin, and the hot-water extracts (L.E.M.) is commercially available as a nutritional supplement.
|
Syringic acid Dilution Calculator
Syringic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.0454 mL | 25.227 mL | 50.4541 mL | 100.9082 mL | 126.1352 mL |
5 mM | 1.0091 mL | 5.0454 mL | 10.0908 mL | 20.1816 mL | 25.227 mL |
10 mM | 0.5045 mL | 2.5227 mL | 5.0454 mL | 10.0908 mL | 12.6135 mL |
50 mM | 0.1009 mL | 0.5045 mL | 1.0091 mL | 2.0182 mL | 2.5227 mL |
100 mM | 0.0505 mL | 0.2523 mL | 0.5045 mL | 1.0091 mL | 1.2614 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,6-Dimethoxy-1,4-benzoquinone
Catalog No.:BCN5698
CAS No.:530-55-2
- Deoxyvasicinone
Catalog No.:BCN5697
CAS No.:530-53-0
- L-Picein
Catalog No.:BCC8336
CAS No.:530-14-3
- Indomethacin
Catalog No.:BCC3794
CAS No.:53-86-1
- Dehydroepiandrosterone
Catalog No.:BCN2202
CAS No.:53-43-0
- Oxandrolone
Catalog No.:BCC5242
CAS No.:53-39-4
- Methylprednisolone acetate
Catalog No.:BCC9043
CAS No.:53-36-1
- Cocaine hydrochloride
Catalog No.:BCC5943
CAS No.:53-21-4
- Mitotane (Lsodren)
Catalog No.:BCC3815
CAS No.:53-19-0
- Estrone
Catalog No.:BCN2201
CAS No.:53-16-7
- Prednisone
Catalog No.:BCC4957
CAS No.:53-03-2
- Acetylisocupressic acid
Catalog No.:BCN5695
CAS No.:52992-82-2
- Sinapic acid
Catalog No.:BCN3539
CAS No.:530-59-6
- CDI (1,1′-Carbonyldiimidazole)
Catalog No.:BCC2809
CAS No.:530-62-1
- Salinomycin
Catalog No.:BCC1916
CAS No.:53003-10-4
- Murralongin
Catalog No.:BCN5696
CAS No.:53011-72-6
- T-5224
Catalog No.:BCC5383
CAS No.:530141-72-1
- Scutebarbatine J
Catalog No.:BCN8134
CAS No.:960302-85-6
- Morellic acid
Catalog No.:BCN3073
CAS No.:5304-71-2
- 9,13-Epidioxy-8(14)-abieten-18-oic acid
Catalog No.:BCN1426
CAS No.:5309-35-3
- Dichotomin
Catalog No.:BCN2836
CAS No.:53093-47-3
- Androsin
Catalog No.:BCN3842
CAS No.:531-28-2
- Coniferin
Catalog No.:BCN5700
CAS No.:531-29-3
- Scopolin
Catalog No.:BCN5701
CAS No.:531-44-2
The Neuroprotective Effect of Syringic Acid on Spinal Cord Ischemia/Reperfusion Injury in Rats.[Pubmed:25903968]
Inflammation. 2015 Oct;38(5):1969-78.
Acute arterial occlusions via different vascular pathologies are the main causes of spinal cord ischemia. We investigated neuroprotective effects of Syringic acid on spinal cord ischemia injury in rats. Rats were divided into four groups: (I) sham-operated control rats, (II) spinal cord ischemia group, (III) spinal cord ischemia group performed Syringic acid, and (IV) spinal cord ischemia group performed methylprednisolone intraperitoneally. Spinal cord ischemia was performed by the infrarenal aorta cross-clamping model. The spinal cord was removed after the procedure. The biochemical and histopathological changes were observed within the samples. Functional assessment was performed for neurological deficit scores. A significant decrease was seen in malondialdehyde levels in group III as compared to group II (P < 0.05). Besides these, nuclear respiratory factor-1 and superoxide dismutase activity of group III were significantly higher than group II (P < 0.05). In histopathological samples, when group III was compared with group II, there was a significant decrease in numbers of apoptotic neurons (P < 0.05). In immunohistochemical staining, BECN1 and caspase-3-immunopositive neurons were significantly decreased in group III compared with group II (P < 0.05). The neurological deficit scores of group III were significantly higher than group II at twenty-fourth hour of ischemia (P < 0.05). Our study revealed that Syringic acid pretreatment in spinal cord ischemia/reperfusion reduced oxidative stress and neuronal degeneration as a neuroprotective agent. Ultrastructural studies are required for Syringic acid to be developed as a promising therapeutic agent to be utilized for human spinal cord ischemia in the future.
Anti-steatotic and anti-inflammatory roles of syringic acid in high-fat diet-induced obese mice.[Pubmed:26838182]
Food Funct. 2016 Feb;7(2):689-97.
This study examined the effects of Syringic acid (SA) on obese diet-induced hepatic dysfunction. Mice were fed high-fat diet (HFD) with or without SA (0.05%, wt/wt) for 16 weeks. SA reduced the body weight, visceral fat mass, serum levels of leptin, TNFalpha, IFNgamma, IL-6 and MCP-1, insulin resistance, hepatic lipid content, droplets and early fibrosis, whereas it elevated the circulation of adiponectin. SA down-regulated lipogenic genes (Cidea, Ppargamma, Srebp-1c, Srebp-2, Hmgcr, Fasn) and inflammatory genes (Tlr4, Myd88, NF-kappaB, Tnfalpha, Il6), whereas it up-regulated fatty acid oxidation genes (Pparalpha, Acsl, Cpt1, Cpt2) in the liver. SA also decreased hepatic lipogenic enzyme activities and elevated fatty acid oxidation enzyme activities relative to the HFD group. These findings suggested that dietary SA possesses anti-obesity, anti-inflammatory and anti-steatotic effects via the regulation of lipid metabolic and inflammatory genes. SA is likely to be a new natural therapeutic agent for obesity or non-alcoholic liver disease.
Syringic acid from Tamarix aucheriana possesses antimitogenic and chemo-sensitizing activities in human colorectal cancer cells.[Pubmed:23745612]
Pharm Biol. 2013 Sep;51(9):1110-24.
CONTEXT: For its variety of biological activities, Tamarix aucheriana (Decne.) Baum. (Tamaricaceae) has an extensive history as a traditional Arab medicine. OBJECTIVES: Antimitogenic and chemo-sensitizing activities of Syringic acid (SA) were studied against human colorectal cancer. MATERIALS AND METHODS: Chromatographic and spectral data were used for the isolation and identification of SA. MTT, flow cytometry, in vitro invasion and angiogenesis assays, fluoremetry, ELISA and Real Time qPCR were used to test antimitogenic and chemo-sensitizing activities of SA, cell cycle, apoptosis, proteasome and NFkappaB-DNA-binding activities, cancer cell invasion and angiogenesis, and expression of cell cycle/apoptosis-related genes. RESULTS: SA showed a time- and dose-dependent (IC(5)(0) = 0.95-1.2 mg mL(-)(1)) antimitogenic effect against cancer cells with little cytotoxicity on normal fibroblasts (=20%). SA-altered cell cycle (S/G2-M or G1/G2-M phases) in a time-dependent manner, induced apoptosis, inhibited DNA-binding activity of NFkappaB (p = 0.0001), chymotrypsin-like/PGPH (peptidyl-glutamyl peptide-hydrolyzing) (p = 0.0001) and the trypsin-like (p = 0.002) activities of 26S proteasome and angiogenesis. SA also differentially sensitized cancer cells to standard chemotherapies with a marked increase in their sensitivity to camptothecin (500-fold), 5FU (20,000-fold), doxorubicin (210-fold), taxol (3134-fold), vinblastine (1000-fold), vincristine (130-fold) and amsacrine (107-fold) compared to standard drugs alone. DISCUSSION: SA exerted its chemotherapeutic and chemo-sensitizing effects through an array of mechanisms including cell-cycle arrest, apoptosis induction, inhibition of cell proliferation, cell migration, angiogenesis, NFkappaB DNA-binding and proteasome activities. CONCLUSION: These results demonstrate the potential of SA as an antimitogenic and chemo-sensitizing agent for human colorectal cancer.
Hepatoprotective effect of syringic acid and vanillic acid on CCl4-induced liver injury.[Pubmed:20522963]
Biol Pharm Bull. 2010;33(6):983-7.
The mycelia of the edible mushroom Lentinula edodes can be cultured in solid medium containing lignin, and the hot-water extracts (L.E.M.) is commercially available as a nutritional supplement. During the cultivation, phenolic compounds, such as Syringic acid and vanillic acid, were produced by lignin-degrading peroxidase secreted from L. edodes mycelia. Since these compounds have radical scavenging activity, we examined their protective effect on oxidative stress in mice with CCl(4)-induced liver injury. We examined the hepatoprotective effect of Syringic acid and vanillic acid on CCl(4)-induced chronic liver injury in mice. The injection of CCl(4) into the peritoneal cavity caused an increase in the serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. The intravenous administration of Syringic acid and vanillic acid significantly decreased the levels of the transaminases. Four weeks of CCl(4) treatment caused a sufficiently excessive deposition of collagen fibrils. An examination of Azan-stained liver sections revealed that Syringic acid and vanillic acid obviously suppressed collagen accumulation and significantly decreased the hepatic hydroxyproline content, which is the quantitative marker of fibrosis. Both of these compounds inhibited the activation of cultured hepatic stellate cells, which play a central role in liver fibrogenesis, and maintained hepatocyte viability. These data suggest that the administration of Syringic acid and vanillic acid could suppress hepatic fibrosis in chronic liver injury.
The protective effect of syringic acid on ischemia injury in rat brain.[Pubmed:25790559]
Turk J Med Sci. 2015;45(1):233-40.
BACKGROUND/AIM: Brain ischemia and treatment are important topics in neurological science. Free oxygen radicals and inflammation formed after ischemia are accepted as the most significant causes of damage. Currently there are studies on many chemopreventive agents to prevent cerebral ischemia damage. Our aim is to research the preventive effect of the active ingredient in Syringic acid, previously unstudied, on oxidative damage in cerebral ischemia. MATERIALS AND METHODS: The rats were randomly divided into 4 groups: control group (no medication or surgical procedure), sham group (artery occlusion), artery occlusion + Syringic acid group sacrificed at 6 h, and artery occlusion + Syringic acid group sacrificed at 24 h. Obtained brain tissue from the right hemisphere was investigated histopathologically and for tissue biochemistry. RESULTS: Superoxide dismutase and nuclear respiratory factor 1 values decreased after ischemia and they increased after Syringic acid treatment, while increased malondialdehyde levels after ischemia were reduced after treatment. Caspase-3 and caspase-9 values increased after ischemia and decreased after treatment; this reduction was more pronounced at 24 h. CONCLUSION: Our study revealed that Syringic acid treatment in cerebral ischemia reduced oxidative stress and neuronal degeneration. In the light of the biochemical and histopathologic results of the present study, we think that Syringic acid treatment may be an alternative treatment method.
Syringic acid ameliorates (L)-NAME-induced hypertension by reducing oxidative stress.[Pubmed:23079793]
Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1175-84.
The objective of the present study was to investigate the effects of Syringic acid (SA), a phenolic acid, on N(omega)-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats. Hypertension was induced in adult male albino rats by oral administration of L-NAME (40 mg/kg/day) dissolved in drinking water daily for 4 weeks. Rats were treated with different doses of SA (25, 50, and 100 mg/kg body weight (b.w.)). Systolic blood pressure of control and experimental rats was recorded. Plasma nitric oxide metabolites (NOx), lipid peroxidative products such as thiobarbituric acid reactive substances, lipid hydroperoxides, conjugated dienes, and antioxidants such as superoxide dismutase, catalase, glutathione peroxidase, vitamin C, vitamin E, and reduced glutathione were estimated in erythrocytes, plasma, and tissues of experimental rats. Hepatic marker enzymes such as aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase and renal functional markers such as urea, uric acid, and creatinine were also estimated in serum. The increased levels of blood pressure, lipid peroxidation products, hepatic and renal function markers, and the decreased level of NOx and antioxidants in L-NAME-induced hypertensive rats were reversed upon SA treatment. The protective effect at the dose of the three tested doses (25, 50, and 100 mg/kg) of SA at a dose of 50 mg/kg b.w. exerts optimum protection. Biochemical findings are substantiated by the histological observation. The protective effects of SA are mediated by reducing oxidative stress and retaining the bioavailability of NO in the cardiovascular system.